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Pancreatic cancer has an abysmal prognosis. Targets for early detection, prevention and therapy are desperately needed.
Inflammatory pathways have an important impact on tumour growth and progression. Expression of BLT2 (the second leukotriene B4
receptor) was investigated by real-time RT–PCR and immunohistochemistry. Cell proliferation was studied after stable transfection
with BLT2, after treatment with siRNA and Compound A as an agonist. BLT2 is expressed in all pancreatic cancer cell lines. Results
from real-time RT–PCR revealed significant overexpression of BLT2 in malignant intraductal papillary mucinous neoplasias (IPMNs)
and pancreatic adenocarcinoma. Intense staining was evident in IPMNs, infiltrating tumour cells and advanced pancreatic intraepithelial
neoplasias (PanINs) but not in normal ductal cells. Overexpression of BLT2 as well as stimulation of Colo357, Panc-1 and AsPC1 cells
with Compound A caused a significant increase in tumour cell proliferation, an effect reversed after siRNA treatment. This study
demonstrates for the first time the expression of BLT2 in the pancreas and overexpression in pancreatic cancers and malignant
IPMNs in particular. Upregulation of BLT2 is already evident in precursor lesions (PanINs, IPMNs). Overexpression of this receptor
leads to significant growth stimulation. Therefore, we suggest BLT2 as a new target for chemoprevention and therapy for pancreatic
cancer.
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Pancreatic cancer is the fourth leading cause of cancer death (after
lung, colon and breast) in the United States and the incidence of
this disease has not declined (Jemal et al, 2006). Indeed it has
increased in African Americans as well as in the Japanese over
recent years (Oomi and Amano, 1998; Lin et al, 1998; Stat bite,
2002; Qiu et al, 2005; Luo et al, 2007). The mortality of pancreatic
cancer almost equals its incidence and most patients die within 6
months because of late diagnosis and lack of effective therapies
(Howard, 1996; Jemal et al, 2006). Potentially curative surgery is an
option only in 9–20% of patients, because of existing liver
metastases or the invasion of major blood vessels (Chua and
Cunningham, 2005). However, even in this selected group 2- and
5-year survival rates are at about 40 and 20%, respectively and the
median survival time is 20 months when patients receive adjuvant
chemotherapy (Neoptolemos et al, 2004; Stocken et al, 2005).
Many patients have recurrent disease 12 months after surgery
because of tumour recurrence or metastatic tumour progression
(Ahrendt and Pitt, 2002; Chua and Cunningham, 2005). Therefore,
identification of risk factors and early diagnostic markers as well
as new therapeutic approaches are desperately needed so that the
disease can be prevented or detected at an early, non-invasive
stage. It is believed that ductal pancreatic adenocarcinomas
originate from ductal cells. Pancreatic intraepithelial neoplasias
(PanINs) are histologically defined lesions in the small ducts and
ductules that are thought to be the precursors of pancreatic cancer
(Hruban et al, 2001). PanINs are potentially an ideal target for
chemoprevention and so a specific marker for these lesions is
likely to be useful for early diagnosis (Hruban et al, 2000, 2001).
Epidemiological and animal studies suggest that a high intake of
polyunsaturated fatty acids (PUFAs) is associated with an
increased incidence and growth of tumours at several specific
organ sites including pancreas, colon, breast and prostate (Rose,
1997; Woutersen et al, 1999a,b). A recent review pointed out the
important role of cyclooxygenase and lipoxygenase pathways in fat
metabolism and in the regulation of pancreatic cancer cell
proliferation and survival (Ding et al, 2003). Cyclooxygenase-2
(COX-2) plays an important role in carcinogenesis, is upregulated
in 56–90% of pancreatic adenocarcinomas and 65% of PanINs and
frequent use of aspirin seems to decrease the risk of pancreatic
cancer (Hitt, 2002; Maitra et al, 2002; Ding et al, 2003). The
5-lipoxygenase (5-LOX) pathway seems to have an even more
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simportant function in pancreatic carcinogenesis (Ding et al, 2003).
Leukotriene B4 (LTB4) is a downstream metabolite of 5-LOX and
stimulates pancreatic cancer cell growth through ERK1/2 phos-
phorylation, which can be inhibited by an LTB4 receptor
antagonist (Tong et al, 2002). However, LY293111 is not specific
as it inhibits 5-LOX activity and is also a PPARg agonist. Recently,
we have reported that the LTB4 receptor 1 (BLT1) is overexpressed
in pancreatic cancer cells and tissues as well as islets adjacent to
the tumour (Hennig et al, 2002). LTB4 receptors are G-protein-
coupled receptors which belong to the chemoattractant receptor
group (Yokomizo et al, 2001). BLT1 was isolated and cloned by
Yokomizo’s group in 1997 (Yokomizo et al, 1997). Three years
later they identified a second, low-affinity receptor for LTB4
(BLT2), with 45% homology with BLT1 at the amino acid level
(Yokomizo et al, 2000). The open reading frame (ORF) of BLT2 is
localised upstream of BLT1 and contains the promoter region of
BLT1. This represents a very rare case of a ‘promoter in ORF’ in
higher eukaryocytes, the physiological significance of which has
not been determined (Yokomizo et al, 2000). BLT1 (352 amino
acids) is almost exclusively expressed in peripheral leukocytes with
low level expression in human spleen and thymus (Yokomizo et al,
1997). However, BLT2 (358 amino acids) is expressed in spleen,
liver, ovary and leukocytes and low levels of its mRNA have been
demonstrated in many tissues (Yokomizo et al, 2000). Recently,
expression of BLT2 in dendritic cells was described, speculating on
a regulatory role in dendritic cell trafficking during induction of
immune responses (Shin et al, 2006). Moreover, BLT2 was found in
mast cells, possibly mediating recruitment and accumulation of
mast cells in areas of inflammation (Lundeen et al, 2006). Further
studies showed by in situ hybridisation that expression of BLT2 is
significantly upregulated in a variety of human cancers (Yoo et al,
2004). In addition, it has been suggested that BLT2 is responsible
for LTB4-induced generation of reactive oxygen species (ROS)
through Rac/ERK and that this receptor is involved in cytokine-
induced differentiation and expansion of haematopoietic stem cells
(Woo et al, 2002; Chung et al, 2005). Stem cell factor and TNF-a
are suggested to regulate BLT2 expression (Lundeen et al, 2006;
Qiu et al, 2006).
There is a strong relationship between chronic inflammation
and development of cancers of the gastrointestinal tract, including
oesophagitis with Barrett’s metaplasia and ultimately oesophageal
adenocarcinoma, inflammatory bowel disease with colon cancer,
and chronic pancreatitis with pancreatic cancer (Orlando, 2002;
Itzkowitz and Yio, 2004; Whitcomb, 2004). The lipoxygenase
pathway in particular has been linked with development and
growth of pancreatic adenocarcinoma, whereas inhibitors of this
pathway, including LY293111, inhibit growth of the cancer
(Hennig et al, 2002; Tong et al, 2002; Ding et al, 2003). As the
function of the second LTB4 receptor in pancreatic cancer is not
known, we investigated the expression and biological importance
of BLT2 in human pancreatic cancer cells and tissues. This study
follows our previous work investigating the function of the
5-lipoxygenase pathway in pancreatic carcinogenesis.
MATERIALS AND METHODS
Materials
RPMI-1640, penicillin–streptomycin solution, trypsin-EDTA solu-
tion were purchased from Gibco (Invitrogen, Karlsruhe, Germany).
Fetal bovine serum (FBS) was from PAA (PAA Laboratories, Co ¨lbe,
Germany).
Compound A and its methyl ester derivative (Compound
B¼control) are gifts from Ono Pharmaceutical Co. Ltd. (Ono
Pharmaceutical Co., Ltd., Chuoku, Osaka, Japan). The BLT2
antibody and LTB4 were purchased from Cayman Chemical Co.
(Ann Arbor, MI, USA).
BLT2 siRNA was purchased from Ambion Inc. (Ambion, Austin,
TX, USA) and negative control siRNA from Qiagen (Qiagen,
Hilden, Germany).
Immunohistochemistry for BLT2
Tissue samples from 10 patients with chronic pancreatitis and 10
with pancreatic ductal adenocarcinoma were examined. As shown
in Table 1, 12 of these surgical pancreatic specimens showed PanIN
lesions. Six specimens showed PanIN-1a and 1b lesions, five had
PanIN-2 and six had PanIN-3 lesions. Ten pancreas specimens
from multi-organ donors were included as controls. However, one
of them contained PanIN-1a lesions.
In addition, seven specimens with benign intraductal papillary
mucinous neoplasias (IPMN), 12 with borderline IPMN and nine
with malignant IPMN were subjected to immunohistochemistry.
Fixation, sectioning and immunohistochemistry were carried out
as described earlier (Hennig et al, 2002). The primary polyclonal
antibody to BLT2 from Cayman Chemicals (Ann Arbor, MI, USA)
was used at 1:50. The stained tissue samples were examined by
two pathologists. Controls included incubation in the absence of
primary antibody and quenching of the primary antibody with the
respective blocking peptide for 1h at room temperature before
application to the tissue.
Cell lines and cell culture
The cell lines used, AsPC-1, Colo357, and Panc-1 were established
from patients with pancreatic adenocarcinoma. The entire human
pancreatic cancer cell lines were purchased from the American
Type Culture Collection (ATCC, Rockville, MA, USA) and grown in
RPMI-1640 medium (Invitrogen Life Technologies, Karlsruhe,
Germany), supplemented with 10% FBS (PAN-Biotech GmbH,
Aidenbach, Germany) and 100Uml
 1 penicillin–streptomycin
(Invitrogen Life Technologies, Karlsruhe, Germany).
Real-time light cycler
s quantitative polymerase chain
reaction (QRT–PCR)
All reagents and equipment for mRNA/cDNA preparation were
purchased from Roche Applied Science Diagnostics (Mannheim,
Germany). mRNA extractions were prepared by automated
isolation using the MagNA Pure LC instrument and isolation kits
I (for cells) and II (for tissue). cDNA was prepared using the first
strand cDNA synthesis kit (AMV) according to the manufacturer’s
instructions. Real-time PCR was performed with the Light Cycler
Fast Start DNA SYBR Green kit. All primers were obtained from
Search-LC (Heidelberg, Germany). Primers for BLT1 were: 50-AC
TGCCTCCAGCCCTCTCAA-30 (forward) and 50-TAGCATTCTGCC
AGGAGGAAA-30 (reverse). Primers for BLT2 were: 50-ACC
TGTAGGCCCAGAAGGATGT-30 (forward) and 50-GAAGTCTTC
CAGCTCAGCAGTGT-30 (reverse). The calculated number of
specific transcripts was normalised to the housekeeping genes
cyclophilin B and hypoxanthine guanine phosphoribosyltransferase,
and expressed as number of copies per microlitre of input cDNA.
Overexpression of BLT2 in pancreatic cancer cell lines
Human BLT2 and formyl-methionyl-leucyl-phenylalanine receptor
(fMLPR) were subcloned into the pcDNA3 expression vector
(Invitrogen Life Technologies, Carlsbad, CA, USA) using BamHI/
EcoRI sites. Colo357, Panc-1 and AsPC-1 cells were cultured in
RPMI-1640 medium supplemented with 10% FBS. For stable
expression of BLT2 or fMLPR, cells were transfected with pcDNA3-
hBLT2 or pcDNA3-hfMLPR using Lipofectamine 2000
TM (Invitro-
gen) and selected with G418 (geneticin) 1.5mgml
 1 (Colo357 and
Panc-1) or 3mgml
 1 (AsPC-1) (Promega Biosciences Inc.,
Mannheim, Germany). The pcDNA3 vector alone and pcDNA3-
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shfMLPR were used as controls. After 2 weeks, the concentration of
G418 was decreased to 0.5mgml
 1. Cells were lysed, RNA was
isolated and the expression of pcDNA3-hBLT2 or pcDNA3-
hfMLPR was confirmed by real-time RT–PCR.
siRNA transfection
Three different sets of siRNA were tested and the most effective set
knocking down BLT2 was used for our experiments. AsPC-1 and
Panc-1 BLT2-transfected pancreatic cancer cells were seeded into
6-well microplates at a concentration of 1–2 10
4 in RPMI-1640
supplemented with 10% FBS (complete medium). After 24h, BLT2
siRNA (sense 50 CCACGCAGUCAACCUUCUGtt 30, antisense
50CAGAAGGUUGACUGCGUGGta 30) or negative control siRNA
(AATTCTCCGAACGTGTCACGT) were added using RNAiFectTH
Transfection Kit (Qiagen, Hilden, Germany) to give a final
concentration of 5mg siRNA per well according to manufacturer’s
instructions.
Medium was changed 24h after transfection, and cells were
grown in complete culture medium.
Table 1 Immunohistochemistry for BLT2 in pancreatitis and pancreatic cancer
Sample Normal ducts PanIN Cancer cells Islet cells Acini
Normal (c.d.)
1 Negative Absent Absent Negative +
2 Negative Absent Absent Negative +
3 Negative 1a: negative Absent Negative +
4 Negative Absent Absent Negative +
5 Negative Absent Absent Negative +
6 Negative Absent Absent + +
7 Negative Absent Absent Negative Negative
8 Negative Absent Absent Negative +
9 Negative Absent Absent + +
10 Negative Absent Absent Negative Negative
CP
1 Negative 1b: +++ Absent +++ +
2 Negative Absent Absent + Negative
3 Negative Absent Absent Negative Absent
4 Negative Absent Absent + Negative
5 Negative Absent Absent Negative Negative
6 Negative Absent Absent Negative Negative
7 Negative Absent Absent Negative Negative
8 Negative 1a: negative Absent + +
9 Negative 1a: negative; 1b: ++ Absent Negative Negative
10 Negative 1a: negative Absent + Negative
PC
1 Absent 3: +++ ++ Negative +
2 Negative 3: +++ ++ Negative +
3 Negative 1b, 2, 3: +++ ++ Absent Absent
4 Negative Absent +++ Negative Negative
5 Absent 1a: negative, 1b: ++ Absent Absent Absent
6 Negative Absent +++ Negative Negative
7 Negative 2: +++ Absent Negative +
8 Negative 2, 3: +++ +++ Negative +
9 Negative 2, 3: +++ +++ Negative Negative
10 Negative 2, 3: +++ +++ Negative Negative
Kruskal–Wallis ANOVA No difference Po0.001 Po0.001 No difference No difference
Normal vs CP P¼0.252 P¼1
Normal vs PC Po0.001 Po0.001
CP vs PC Po0.001 Po0.001
c.d.¼cadaver donor; CP¼chronic pancreatitis; PC¼pancreatic cancer.On account of the multiple groups, statistical analysis in the human samples was carried out by Kruskal–
Wallis one-way ANOVA with Dunn’s method as post hoc test for multiple comparisons. PanIN: pancreatic intraepithelial neoplasia, grade 1a, 1b, 2 and 3. Absent: described
structures are not present in this tissue section. Negative: unstained but present structures. ‘+’ Weak positive staining. ‘++’ Positive staining. ‘+++’ Strong positive staining.
Figure 1 Immunohistochemical localisation of BLT2 in human pancreatic tissues. A–Ishows normal pancreatic tissues obtained from multi-organ donors,
chronic pancreatitis and pancreatic adenocarcinoma stained by the AP-Red system. K–P demonstrates staining in IPMN tissues using the DAB system.
(A) unstained duct in normal pancreas ( 400); (B) unstained PanIN-1a lesion in normal pancreas ( 400); (C) unstained ducts in chronic pancreatitis and
basal staining in some acinar cells ( 400). (D) PanIN-2 lesion in chronic pancreatitis with positive staining in the cytoplasm ( 200); (E) and (F) PanIN-3
lesion in pancreatic cancer with intense cytoplasmic staining ( 200,  400); (G) unstained PanIN-3 lesion in an adjacent section to (F) but in the presence
of the blocking peptide to quench the staining ( 400); (H) infiltrating tumour cells in pancreatic cancer with marked positive staining in the cytoplasm
( 400); (I) positive-stained tumour cells in a lymph node metastasis ( 400); (K) unstained normal duct next to an IPMN adenoma ( 200); intense
cytoplasmic staining is shown in (L) IPMN adenoma branch duct type ( 100), (M) main duct type ( 400), (N) borderline IPMN of the oncocytic type
( 200), and in malignant invasive IPMNs of the (O) tubular ( 200) and (P) colloid type ( 400). The primary antibody to BLT2 was used at 1:50 on
deparaffinised tissues.
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sNext, mRNA was extracted after 48h of transfection using the
MagNA Pure LC instrument and isolation kits I (for cells) for
QRT–PCR analysis.
Proliferation studies: in tumour cells overexpressing BLT2
AsPC-1, Panc-1 and Colo357 Mock, fMLPR and BLT2-transfected
pancreatic cancer cells were seeded into 6-well microplates at a
concentration of 1 10
4cells per well for AsPC-1, 2 10
4cells per
well for Colo357 and 4 10
4cells per well for Panc-1 and incubated
at 371C in RPMI-1640 supplemented with 10% FBS. After 24,
48, 72, 96 and 120h cells were harvested and viable cells counted
using Guava PC (Guava-PC Technologies, Hayward, CA, USA). In
addition, proliferation was analysed by 3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium bromide (MTT) assay.
Proliferation studies: in tumour cells treated with BLT2
ligands
In further studies cells were seeded into 12-well microplates in
complete medium (30–50% confluence). After 24h, cells were
cultured in serum-free media with or without different concentra-
tions of LTB4, Compound A and Compound B (control) for 24, 48,
72, 96, and 120h. Medium was changed after 48h. At the end of
each time point, the cells were trypsinised to produce single cell
suspension and the viable cell number in each well counted using
Guava PC (Guava Technologies, Hayward, CA, USA). For MTT
assay cells were seeded into 12-well microplates in complete
medium at a concentration of 2 10
4cells per well. After 24h, cells
were cultured in serum-free media with or without different
concentrations of LTB4, Compound A and Compound B (control)
for 24, 48, 72 and 96h. Medium was changed after 48h. At the end
of each time period 5mgml
 1 MTT was added.
Proliferation studies: in tumour cells treated with BLT2
siRNA
For the siRNA proliferation studies, cells were trypsinised and the
viable cell number was counted at 24, 48, 72, 96 and 120h after cell
seeding using Guava PC (Guava Technologies, Hayward, CA,
USA).
Proliferation studies: in tumour cells treated with BLT2
ligands and siRNA
In an additional experiment, cells were seeded into 12-well
microplates in complete medium (30–50% confluence). After
24h, cells were cultured in serum-free medium with or without
Compound A and Compound B (control) for 48h. At this time
point, the medium was changed and BLT2 siRNA (sense 50
CCACGCAGUCAACCUUCUGtt 30, antisense 50CAGAAGGUU
GACUGCGUGGta 30) or negative control siRNA (AATTCTCC
GAACGTGTCACGT) were added using RNAiFectTH Transfection
Kit (Qiagen, Hilden, Germany) to give a final concentration of 5mg
siRNA per well according to manufacturer’s instructions. The
medium was changed 12h after transfection, and the cells were left
to grow in complete culture medium for another 12h. Twenty-four
hours after siRNA transfection, the medium was changed and cells
were grown in complete culture medium with or without
Compound A and Compound B (control) for another 24 and
48h under siRNA effect and then counted using Guava PC (Guava
Technologies, Hayward, CA, USA).
STATISTICAL ANALYSIS
Proliferation studies have been repeated at least three times
independently. Data on BLT2 expression by immunohisto-
chemistry in humans were analysed by Kruskal–Wallis one-way
ANOVA with the Dunn’s method as post hoc test. Results
from QRT–PCR were analysed using one-way ANOVA with the
Student–Newman–Keul’s Method as post hoc test for multiple
paired comparisons. Paired t-test and Friedman repeated measures
analysis of variance on ranks (with Tukey’s as post hoc test for
pairwise multiple comparisons) were used to analyse cell
proliferation (cell counting).
RESULTS
Expression of BLT2 in human pancreatic tissues
BLT2 were found to be markedly upregulated in PanIN lesions and
cancer cells, but were not expressed in islet cells, except in
four specimens obtained from patients with chronic pancreatitis
(Figure 1). PanIN-1a lesions and normal ductal cells
showed absolutely no staining for BLT2, however, we observed
strong positive staining in all PanIN-1b, two and three
lesions which were found in 8 of 10 pancreatic adenocarcinoma
tissues and in two specimens from patients with chronic
pancreatitis (Figure 1). The other eight chronic pancreatitis
tissues contained either normal ducts and/or PanIN-1a lesions,
which did not stain for BLT2. Furthermore, infiltrating tumour
cells showed strong positive staining in pancreatic adenocarcino-
ma tissues and in a lymph node metastasis (Figure 1). Acinar cells
in normal pancreas, chronic pancreatitis and pancreatic adeno-
carcinoma sporadically showed BLT2 expression in the cytoplasm
adjacent to the basolateral membrane. Details are shown in
Table 1.
In addition, immunohistochemistry was performed in a variety
of pancreatic tissues showing IPMN lesions. Moderate (12 of 28) or
strong (13 of 28) cytoplasmic staining for BLT2 was detected in 25
of 28 tissues with IPMNs regardless of whether they were benign or
malignant or if they are main or branch duct type lesions
(Figure 1). Acinar cells did not stain for BLT2. Islet cells, when
applicable, showed weak (16 of 28) or moderate (3 of 28)
expression of BLT2 in their cytoplasm. Details are shown in
Table 2. Negative controls for BLT1 and BLT2 (first antibodies
quenched with the appropriate blocking peptides) showed no
staining (Figure 1). In most sections, inflammatory cells stained
positive for BLT2 and this provided a valuable internal control.
In normal tissues and tissues containing only PanIN1a lesions,
these were the only cells with significant staining. It is likely that
these were mast cells, but we did not confirm this by double
staining.
The results obtained from QRT–PCR confirmed the immuno-
histochemical findings. BLT1 and BLT2 mRNA were upregulated
in chronic pancreatitis and malignant pancreatic tissues. BLT1
expression is approximately fivefold higher than BLT2. Further-
more, although BLT2 is significantly overexpressed only in
malignant pancreatic tissues, BLT1 is also significantly upregulated
in tissues from patients with chronic pancreatitis (Figure 2).
Expression of BLT1 and BLT2 in human pancreatic cancer
cells
Both, BLT1 and BLT2 were found to be expressed at the mRNA
level in all human pancreatic cancer cell lines (MiaPaCa2, AsPC-1,
T3M4, Panc-1, Su8686, Capan1, BxPC3, Colo357) tested. Real-time
RT–PCR revealed that expression levels of both receptors differed
between cell lines, with approximately 2-fold higher BLT1 mRNA
expression compared with BLT2 expression (Po0.001). MiaPaCa2
cells showed the highest expression for both receptors compared
with the other cell lines (BLT1 all Po0.005; BLT2 all Po0.05)
(Figure 3).
BLT2 expression in pancreatic cancer
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tumour cell proliferation
The effect of stable overexpression of BLT2 on cell proliferation
was studied in AsPC-1, Panc-1 and Colo357 cells (AsPC-1-BLT2,
Panc-1-BLT2 and Colo357-BLT2 cells, respectively). Receptor
mRNA levels increased after BLT2 transfection from 50 to 4176
transcripts per microlitre in Colo357, from 95 to 11310 transcripts
per microlitre in Panc-1 and from 142 to 1004 transcripts per
microlitre in AsPC-1 cells. BLT2 mRNA levels remained stable on
the basal expression level after transfection with hfMLPR or the
empty pcDNA3 vector (mock). Proliferation over 96 and 120h was
significantly increased in Panc-1-BLT2, Colo357-BLT2 and AsPC-
1-BLT2 cells, respectively compared with Panc-1-hfMLPR,
Colo357-hfMLPR and AsPC-1-hfMLPR cells as well as their mock
transfected clones, measured by cell counting (Po0.001) (Figure 4)
and MTT assay (Po0.001) (data not shown).
The effect of BLT2 overexpression on tumour cell proliferation
was inhibited by siRNA transfection. After 48h BLT2 mRNA levels
decreased from 2583 to 802 transcripts per microlitre in Panc-1
and from 2198 to 830 transcripts per microlitre in AsPC-1 cells,
causing significant growth inhibition of Panc-1-BLT2 and AsPC-1-
BLT2 cells (Po0.001). Despite several attempts, we were not
able to successfully transfect Colo357 cells with BLT2 siRNA.
Transfection of scrambled siRNA as control did not change the
proliferation of Panc-1-BLT2, AsPC-1-BLT2, Panc-1-hfMLPR and
AsPC-1-hfMLPR cells. Data are illustrated for Panc-1 in Figure 4.
In tumour cells that do not overexpress BLT2, we observed
significant growth inhibition by BLT2 siRNA when BLT2 was
stimulated with Compound A but not without stimulation
(Figure 5).
Effects of BLT2 agonists on tumour cell proliferation
The selective synthetic BLT2 agonist, Compound A, caused
significant growth stimulation of pancreatic cancer cells in a
concentration- and time-dependent manner. The final dose of
1000nM we used in our time-dependent experiments might be
high, but is reasonable as the metabolism and half-life of
Compound A are not known. Compound B, its methyl ester
derivative without any stimulatory effects on BLT2 (Iizuka et al,
2005) used as a negative control, did not alter proliferation of these
tumour cells. Treatment of pancreatic cancer cells with the
common BLT1 and BLT2 agonist LTB4 caused an additional
growth advantage when compared with cells treated with
Compound A or B. Proliferation was measured by cell counting
and MTT assay. Data for the treatment of Colo357 and Panc-1 cells
are shown in Figure 5.
Table 2 Immunohistochemistry for BLT2 in IPMNs
Sample Normal ducts IPMN Cancer cells Islet cells Acini
IPMN-adenoma
1 + + Absent Negative Negative
2 + +++ Absent + Negative
3 + +++ Absent + Negative
4 Negative ++ Absent + Negative
5 + +++ Absent + Negative
6 + +++ Absent ++ Negative
7 ++ ++ Absent ++ Negative
IPMN-borderline
1 + ++ Absent + Negative
2 + ++ Absent + Negative
3 + ++ Absent + Negative
4 + +++ Absent + Negative
5 ++ ++ Absent + Negative
6 + + Absent + Negative
7 ++ +++ Absent ++ Negative
8 + ++ Absent + Negative
9 + +++ Absent Absent Absent
10 + +++ Absent + Absent
11 + ++ Absent + Negative
12 ++ +++ Absent + Negative
IPMN-malignant
1 Absent ++ ++ Absent Absent
2 Absent +++ +++ Absent Absent
3 Absent +++ +++ Absent Absent
4 + +++ +++ + Absent
5 + +++ +++ + Negative
6 Absent ++ ++ Absent Absent
7 Absent ++ ++ Absent Absent
8 Absent ++ ++ Absent Absent
9 Absent Negative Negative Absent Absent
Kruskal–Wallis ANOVA No difference P¼0.896 Po0.001 No difference No difference
Adenoma vs borderline P¼1
Adenoma vs malignant Po0.001
Borderline vs malignant Po0.001
IPMN¼intraductal papillary mucinous neoplasia. On account of the multiple groups, statistical analysis in the human samples was carried out by Kruskal–Wallis one-way
ANOVA with Dunn’s method as post hoc test for multiple comparisons. Absent: described structures are not present in this tissue section. Negative: unstained but present
structures. ‘+’ Weak positive staining. ‘++’ Positive staining. ‘+++’ Strong positive staining.
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sDISCUSSION
Arachidonic acid is the precursor of eicosanoids, which are
important mediators involved in inflammation as well as in the
growth of different cancers, including colon, prostate, breast, lung
and pancreatic adenocarcinoma (Ding et al, 2003). There are two
major groups of eicosanoids: (1) prostaglandins, that are produced
by cyclooxygenases and (2) leukotrienes, that are generated by
5-lipoxygenase (5-LOX). Leukotrienes are potent pro-inflamma-
tory mediators that have important functions in inflammatory
disorders and allergies (Sampson, 2000; Shao et al, 2006). Recently,
we and others have demonstrated that leukotrienes may also be
important in cancer development, metastases and cachexia
(Paruchuri et al, 2002, 2006; Tong et al, 2002). In the BOP-hamster
model leukotriene concentration was significantly increased in
pancreatic carcinoma when compared with tumour-free tissue
(Heukamp et al, 2006). Moreover, fish oil (rich in n-3 PUFAs)
decreased the incidence of liver metastases, possibly because of
decreased intrametastatic leukotriene concentration (Heukamp
et al, 2006). Expression of the leukotriene D4 receptor (CysLT1)i s
increased in colorectal adenocarcinomas and leukotriene D4
(LTD4) and LTB4 stimulate colon cancer cell proliferation by
activating ERK1/2 (Paruchuri et al, 2002, 2006; Nielsen et al, 2003,
2005; Ohd et al, 2003). Furthermore, inhibitors of leukotriene
production can effectively prevent the lung cancer development in
mice (Gunning et al, 2002). We have recently shown, that LTB4
stimulates pancreatic cancer cell growth by activating ERK1/2; an
effect inhibited by the unspecific LTB4 receptor antagonist,
LY293111 (Tong et al, 2002, 2007). We previously demonstrated
the expression of BLT1 in human pancreatic cancer tissues with
strong staining in cancer cells and the islets surrounding these
tumours (Hennig et al, 2002). BLT2 mRNA expression was
demonstrated in murine and human mast cells responsible for
recruitment and accumulation of mast cells in areas of inflamma-
tion (Lundeen et al, 2006). Another study described a TNFa-
dependent expression of BLT2 in human umbilical vein endothelial
cells which may be important during early vascular responses to
inflammation (Qiu et al, 2006). In addition, greatly increased BLT2
mRNA levels were found in a variety of human cancers by in situ
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Figure 2 Expression of BLT1 and BLT2 on mRNA level in human pancreatic tissues using real-time RT–PCR (NP¼normal pancreas obtained from
multi-organ donors, CP¼chronic pancreatitis, PC¼pancreatic adenocarcinoma, IPMN¼intraductal papillary mucinous neoplasia). (A) shows BLT1
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Figure 3 Expression of BLT1 and BLT2 on mRNA level in pancreatic
cancer cell lines using real-time RT–PCR.
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shybridisation (Yoo et al, 2004). Pancreatic specimens were not a
subject of this study (Yoo et al, 2004). Yoo et al (2004) suggested
that a LTB4-BLT2-linked cascade has a crucial mediatory function
in cell transformation induced by oncogenic Ha-Ras
V12. LY255283
has been described as a selective BLT2 antagonist (Qiu et al, 2006;
Shin et al, 2006). However, other results demonstrate unspecificity
of LY255283 for BLT2. Until now, no specific BLT2 inhibitor is
available. Very recently, Choi et al (2007) could demonstrate
that BLT2 is a key regulator of ROS in H-Ras
V12-transformed
fibroblasts and suggested a LTB4-BLT2-Nox1-linked cascade
responsible for elevated ROS generation in Ras-transformed cells.
However, there is still limited information on the physiological
role of BLT2 in cancer and this receptor has not been previously
linked to pancreatic cancer. The current results demonstrate the
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Figure 4 The effect of overexpression of BLT2 in Panc-1 (A), Colo357 (B) and AsPC-1 (C) cells on proliferation of these cells, evaluated by cell counting
over 96 and 120h. Significant growth stimulation is shown for BLT2-transfected cells compared with Mock and fMLPR (Po0.001). Reversibility of this effect
after siRNA transfection is demonstrated for Panc-1 cells by cell counting over 120h (D). (Po0.001 for BLT2 siRNA sc vs BLT2 siRNA BLT2 and BLT2
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Figure 5 Treatment with LTB4 (BLT1 and BLT2 agonist) or Compound A (selective BLT2 agonist) significantly increased proliferation of Panc-1 and
Colo357 cells dose (over 48h; *Po0.05; **Po0.01) and time dependently (at 1000nM; Po0.001 for LTB4 and Compound A vs Compound B). Compound
B is a methyl ester and served as negative control. Dose-dependent effects are shown in (A) and time-dependent effects in (B) and (C). Panel (D)
demonstrates significant growth inhibition of Panc-1 cells (not overexpressing BLT2) by BLT2 siRNA when BLT2 is stimulated with Compound A.
The black arrow marks when siRNA was added.
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sexpression of BLT2 in all human pancreatic cancer cell lines tested
and overexpression in all the human pancreatic tissues obtained
from patients with pancreatic adenocarcinoma and chronic
pancreatitis, when PanIN lesions are present. BLT2 is also
upregulated in IPMNs. Strong BLT2 staining was seen in all
grades of PanINs, except PanIN-1a. BLT2 staining was also intense
in benign and malignant IPMNs; another progression model for
pancreatic cancer. BLT2 was significantly upregulated in malignant
IPMNs when compared with benign IPMNs and normal pancreatic
specimens. However, all IPMNs, including the benign lesions
showed specific staining for BLT2. This might be explained by the
fact that complete tumour specimens and not microdissected
IPMNs were subjected to quantitative RT–PCR and benign IPMNs
are often smaller than malignant IPMNs.
Overexpression of BLT2 in three different human pancreatic
cancer cell lines resulted in increased proliferation compared with
control cells transfected with either hfMLPR or empty vector. This
is consistent with our previous findings that LTB4 stimulates
pancreatic cancer cell growth (Tong et al, 2002). Pancreatic cancer
cells secrete LTB4 and produce growth factors such as epidermal
growth factor (EGF). In addition, EGF is able to stimulate LTB4
production and secretion in these cells. Therefore, LTB4 may be
involved in the autocrine growth stimulation of pancreatic cancer
cells acting on both receptors. This might explain why recombi-
nant overexpression of BLT2 in cancer cells already expressing
endogenous BLT2 have a growth advantage without any further
treatment, because more receptor-binding sites (BLT2) can be
stimulated by LTB4. Moreover, serum contains so far unspecified
lipid factors stimulating BLT2. Furthermore, LTB4 has previously
been linked to insulin secretion. As we observed that BLT1 is
upregulated in islets adjacent to pancreatic adenocarcinoma, it is
tempting to speculate that the tumours may induce additional
paracrine growth stimulation by augmenting local insulin secre-
tion in the pancreas (Pek and Walsh, 1984; Hennig et al, 2002).
Selective BLT2 stimulation with Compound A and inhibition
with siRNA caused increased tumour cell proliferation or growth
inhibition, respectively. However, siRNA treatment of cancer cells
expressing endogenous BLT2 did not affect their proliferation rate.
This is difficult to fully explain, because if endogenous LTB4
stimulates growth through BLT2 receptors, then receptor knock-
down would be expected to reduce proliferation. However, the
answer may lie in the fact that both receptor subtypes respond to
this ligand. Reduction in copy number of BLT2 may merely allow
the LTB4 to signal through the BLT1, which have higher affinity for
the ligand. However, in cells with upregulated BLT2, knockdown
will reveal the growth effects of this receptor. Evidence that this
explanation is correct comes from the experiments with Com-
pound A in cells (a compound that is relatively specific for BLT2)
without overexpression of BLT2. Here, the BLT2 knockdown did
block proliferation.
As BLT2 are not or only weakly expressed in normal ductal
cells, their marked upregulation in PanINs, IPMNs and infiltrating
cancer cells suggests a beneficial role of this receptor for the
cancer cells. To our knowledge, this is the first report linking BLT2
to pancreatic cancer. We may have found a selective PanIN
and IPMN marker. Maitra et al (2002) reported that COX-2 is
overexpressed in 65% of PanIN lesions and suggested the use of
COX-inhibitors for chemoprevention in patients at high risk.
However, COX-2 is not expressed in all PanIN lesions and is
also expressed in islets (Maitra et al, 2002). BLT2 may prove to be a
superior target, because of the consistent and selective expression
in PanINs and IPMNs. We speculate that upregulation of
BLT2 is associated with ductal changes. However, we do not claim
BLT2 as a specific marker for pancreatic carcinogenesis. BLT2
could be considered as an imaging target for early neoplastic
lesions, for example, in patients at high risk for pancreatic
cancer. The expected background signal in normal pancreas
should be sufficiently low, because acinar and islet cells only
showed weak positive staining in some tissues and BLT2 mRNA
levels in whole pancreas are very low compared with other organs.
Finally, development of a combined BLT1 and BLT2 antagonist
(Hicks et al, 2007) could be a valuable approach for the treatment
and chemoprevention of pancreatic and perhaps other cancers.
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